HDAC抑制剂在非小细胞肺癌的临床试验研究进展(英文)

• 作 者: Xingsheng Hu Lin Wang Lin Lin Yuankai Shi
• 机 构: Beijing Key Laboratory of Clinical Research on Molecular-targeted Antitumor Agents, Department of Me
• 出 处: The Chinese-German Journal of Clinical Oncology
• 发表日期: 2014年04期
• 关键词: 非小细胞肺癌 临床试验研究 structurally Histone 抑制剂 diverse approved paclitaxel deacetylase e

Histone deacetylase(HDAC) inhibitors, which represent a structurally diverse group of molecules, have emerged as a novel therapeutic class of molecules with significant anticancer potential. Vorinostat and romidepsin, known as the first generation of HDAC inhibitors, were approved in the United States for the treatment of T-cell lymphomas. Preliminary activity of HDAC inhibitors has also been observed in non-small cell lung cancer(NSCLC) in combination with the existing treatment regimens, of which is the focus of the current review.

Histone deacetylase (HDAC) inhibitors, which represent a structurally diverse group of molecules, have emerged as a novel therapeutic class of molecules with significant anticancer potential. Vorinostat and romidepsin, known as the first generation of HDAC inhibitors, were approved in the United States for the treatment of T-cell lymphomas. Preliminary activity of HDAC inhibitors has also been observed in non-small cell lung cancer (NSCLC) in combination with the existing treatment regimens, of which is the focus of the current review.